As AI shakes up pharma and biotech, can patent law keep up?

Artificial intelligence is undoubtedly impacting the biotech lifecycle, and presents myriad applications—and risks. Tim Powell, Vishnu Shankar and Ben Rowlatt of Morgan Lewis provide a detailed analysis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

INTA unveils key principles on AI and IP rights at Annual Meeting

20 May 2025 The International Trademark Association launches a regulatory framework for AI at the Annual Meeting in San Diego | Adopted Resolution highlights importance of human oversight in IP decisions.

Americas

LSPN: Counsel grapple with AI’s impact on training and critical thinking

8 May 2025 Legal heads from Pfizer and The Broad Institute stress the need for cross-disciplinary teams and careful training as AI software becomes mainstream, reports Marisa Woutersen from LSPN 2025.

Americas

Strategic IP protection for biotech-related GenAI

24 April 2025 Generative AI is transforming the biotech industry, so it’s crucial to have an IP strategy—in particular, for trade secret and/or patent protection. Dean Pelletier of Pelletier Law explains.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

As AI shakes up pharma and biotech, can patent law keep up?

More on this story

Editor's picks

Editor's picks

More features